Federal Register / Vol. 86, No. 158 / Thursday, August 19, 2021 / Notices 46707 

in control versus Tg(hs:miR-101a-sp) 

hearts in Figure 4J of Development 

2015 

—differences in (1) the amount of 

scarring, as represented by comparing 

AFOG staining in control and 

Tg(hs:miR-101a-sp) and Tg(hs:miR133a1-pre) hearts exposed to long 

term heat therapy in Figures 5A, 5B 

and 5C, or Tropomyosin staining in 

Figures 5D, 5E, and 5F; and (2) the 

quantification of the scarring indices, 

tropomyosin expression, and injury 

area in Figures 5G, 5H, and 5I of 

Development 2015 

—increased Fosab expression in 

Tg(hs:miR-101a-sp) ventricles relative 

to controls in Figures 6A and 6B, RNA 

in situ hybridization studies in 

control and regenerating hearts 

detecting miR-101a expression in 

Figures 6C, 6D, 6E, and 6E’, and Fosab 

expression in Figures 6F, 6G, 6H, and 

6H’ of Development 2015 

—images reporting significant 

differences in Dsred expression, 

cardiomyocyte proliferation, collagen 

and fibrin staining, and scar tissue 

removal in ventricles from zebrafish 

treated with lna-Let-7, as compared to 

scrambled control, to support the 

importance of miR-101a in scar tissue 

removal/ventricular regeneration in 

Figures 6H, 6I, 6J, 7C, 7D, and 7E of 

Development 2015 

• reporting research methods and 

statistics that were not performed in the 

following experimental results: 

—PCR data in the graph represented in 

Figure 2B of PNAS 2018 draft, 

iScience 2018 draft, and iScience 

2019, by representing the data from 

two (2) remote PCR experiments as 

being from the same experiment 

—PCR data in the graph represented in 

Figure 2B of iScience Correction by 

reusing and relabeling a graph 

containing data that were the result of 

different experimental conditions 

(exposure to heat shock), to include 

scrambled control data 

—control data and statistical differences 

between control and experimental 

data represented in PNAS 2018 draft, 

iScience 2018 draft, iScience 2019, 

and iScience Correction, by falsely 

reporting the use of both antisense 

scrambled and LNA oligonucleotides 

that were designed and administered 

to adult animals via intraperitoneal 

injection at 10ug/g body weight 

—representing the ‘‘n’’ of one biological 

replicate or one experiment as being 

multiple independent samples or 

experiments in iScience 2019 and 

iScience Correction 

—control data and statistical differences 

between control and experimental 

data and the reported methods in 

Development 2015, concluding that 

miR-101a controls both CM 

proliferation and scar tissue removal, 

by falsely reporting the use of LNA 

oligonucleotides to modulate miR-101 

activity in vivo to elucidate its 

contributions during adult heart 

regeneration 

Dr. Yin entered into a Voluntary 

Settlement Agreement (Agreement) and 

voluntarily agreed to the following: 

(1) Respondent agreed to have his 

research supervised for a period of two 

(2) years beginning on August 2, 2021. 

Respondent agreed that prior to 

submission of an application for PHS 

support for a research project on which 

Respondent’s participation is proposed 

and prior to Respondent’s participation 

in any capacity on PHS-supported 

research, Respondent shall ensure that a 

plan for supervision of Respondent’s 

duties is submitted to ORI for approval. 

The supervision plan must be designed 

to ensure the scientific integrity of 

Respondent’s research contribution. 

Respondent agreed that he shall not 

participate in any PHS-supported 

research until such a supervision plan is 

submitted to and approved by ORI. 

Respondent agreed to maintain 

responsibility for compliance with the 

agreed upon supervision plan. 

(2) The requirements for Respondent’s 

supervision plan are as follows: 

i. A committee of 2–3 senior faculty 

members at the institution who are 

familiar with Respondent’s field of 

research, but not including 

Respondent’s supervisor or 

collaborators, will provide oversight and 

guidance for a period of two (2) years 

from the effective date of the 

Agreement. The committee will review 

primary data from Respondent’s 

laboratory on a quarterly basis and 

submit a report to ORI at six (6) month 

intervals setting forth the committee 

meeting dates and Respondent’s 

compliance with appropriate research 

standards and confirming the integrity 

of Respondent’s research. 

ii. The committee will conduct an 

advance review of any PHS grant 

applications (including supplements, 

resubmissions, etc.), manuscripts 

reporting PHS-funded research 

submitted for publication, and abstracts. 

The review will include a discussion 

with Respondent of the primary data 

represented in those documents and 

will include a certification to ORI that 

the data presented in the proposed 

application/publication is supported by 

the research record. 

(3) Respondent agreed that for a 

period of two (2) years beginning on 

August 2, 2021, any institution 

employing him shall submit, in 

conjunction with each application of 

PHS funds, or report, manuscript, or 

abstract involving PHS-supported 

research in which Respondent is 

involved, a certification to ORI that the 

data provided by Respondent are based 

on actual experiments or are otherwise 

legitimately derived and that the data, 

procedures, and methodology are 

accurately reported in the application, 

report, manuscript or abstract. 

(4) If no supervisory plan is provided 

to ORI, Respondent agreed to provide 

certification to ORI at the conclusion of 

the supervision period that he has not 

engaged in, applied for, or had his name 

included on any application, proposal, 

or other request for PHS funds without 

prior notification to ORI. 

(5) Respondent agreed to exclude 

himself voluntarily from serving in any 

advisory capacity to PHS including, but 

not limited to, service on any PHS 

advisory committee, board, and/or peer 

review committee, or as a consultant for 

a period of two (2) years, beginning on 

August 2, 2021. 

(6) As a condition of the Agreement, 

Respondent will request that the 

following papers be retracted in 

accordance with 42 CFR 93.407(a)(1) 

and § 93.411(b): 

• Development 2015 Dec 

1;142(23):4026–37 

• iScience 2019 May 31;15:1–15 

• iScience 2019 Jul 26;17:225–29 

Respondent will copy ORI and the 

Research Integrity Officer at MDIBL on 

the correspondence. 

Dated: August 16, 2021. 

Wanda K. Jones, 

Acting Director, Office of Research Integrity, 

Office of the Assistant Secretary for Health. 

[FR Doc. 2021–17777 Filed 8–18–21; 8:45 am] 

BILLING CODE 4150–31–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Meeting 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the National Cancer Institute 

Clinical Trials and Translational 

Research Advisory Committee. 

The meeting will be held as a virtual 

meeting and is open to the public. 

Individuals who plan to view the virtual 

meeting and need special assistance or 

other reasonable accommodations to 

view the meeting, should notify the 


lotter on DSK11XQN23PROD with NOTICES1
46708 Federal Register / Vol. 86, No. 158 / Thursday, August 19, 2021 / Notices 

Contact Person listed below in advance 

of the meeting. The meeting will be 

videocast and can be accessed from the 

NIH Videocasting and Podcasting 

website (http://videocast.nih.gov). 

Name of Committee: National Cancer 

Institute Clinical Trials and Translational 

Research Advisory Committee. 

Date: November 10, 2021. 

Time: 11:00 a.m. to 3:00 p.m. 

Agenda: Strategic Discussion of NCI’s 

Clinical and Translational Research 

Programs. 

Place: National Cancer Institute, 9609 

Medical Center Drive, Rockville, MD 20850 

(Virtual Meeting). 

Contact Person: Sheila A. Prindiville, M.D., 

M.P.H., Director, Coordinating Center for 

Clinical Trials, National Cancer Institute, 

National Institutes of Health, 9609 Medical 

Center Drive, Room 6W136, Rockville, MD 

20850, 240–276–6173, prindivs@

mail.nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

Information is also available on the 

Institute’s/Center’s home page: http://

deainfo.nci.nih.gov/advisory/ctac/ctac.htm, 

where an agenda and any additional 

information for the meeting will be posted 

when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: August 16, 2021. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–17821 Filed 8–18–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Environmental 

Health Sciences; Amended Notice of 

Meeting 

Notice is hereby given of a change in 

the meeting of the National Advisory 

Environmental Health Sciences Council, 

September 13, 2021, 11:00 a.m. to 

September 14, 2021, 04:45 p.m., 

National Institute of Environmental 

Health Science, Durham, NC 27709 

which was published in the Federal 

Register on August 16, 2021, FR Doc 

2021–17410, 86 FR 45742. 

This notice is being amended to 

change the meeting date from 

September 13–14, 2021 to September 

13, 2021. The start time for open session 

is also amended and will now start at 

11:45 a.m. and adjourn at 5:15 p.m. The 

meeting is partially closed to the public. 

Dated: August 16, 2021. 

David Freeman, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–17819 Filed 8–18–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; SEP–5: NCI 

Clinical and Translational Cancer Research. 

Date: October 6–7, 2021. 

Time: 10:00 a.m. to 2:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute at Shady 

Grove, 9609 Medical Center Drive, Room 

7W248, Rockville, Maryland 20850 

(Telephone Conference Call). 

Contact Person: Shree Ram Singh, Ph.D., 

Scientific Review Officer, Special Review 

Branch, Division of Extramural Activities, 

National Cancer Institute, NIH, 9609 Medical 

Center Drive, Room 7W248, Rockville, 

Maryland 20850, 240–672–6175, singhshr@

mail.nih.gov. 

Name of Committee: National Cancer 

Institute Initial Review Group; Career 

Development Study Section (J). 

Date: October 12–13, 2021. 

Time: 10:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute at Shady 

Grove, 9609 Medical Center Drive, Room 

7W624, Rockville, Maryland 20850 

(Telephone Conference Call). 

Contact Person: Tushar Deb, Ph.D., 

Scientific Review Officer, Resources & 

Training Review Branch, Division of 

Extramural Activities, National Cancer 

Institute, NIH, 9609 Medical Center Drive, 

Room 7W624, Rockville, Maryland 20850, 

240–276–6132, tushar.deb@nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; 

Strengthening Institutional Capacity to 

Conduct Global Cancer Research in Low- and 

Middle-Income Countries. 

Date: October 12, 2021. 

Time: 12:00 p.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute at Shady 

Grove, 9609 Medical Center Drive, Room 

7W248, Rockville, Maryland 20850 

(Telephone Conference Call). 

Contact Person: Shree Ram Singh, Ph.D., 

Scientific Review Officer, Special Review 

Branch, Division of Extramural Activities, 

National Cancer Institute, NIH, 9609 Medical 

Center Drive, Room 7W248, Rockville, 

Maryland 20850, 240–672–6175, singhshr@

mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; NCI 

Review of Informatics Technology in Cancer 

Research. 

Date: October 14–15, 2021. 

Time: 11:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute at Shady 

Grove, 9609 Medical Center Drive, Room 

7W640, Rockville, Maryland 20850 

(Telephone Conference Call). 

Contact Person: Saejeong J. Kim, Ph.D., 

Scientific Review Officer, Special Review 

Branch, Division of Extramural Activities, 

National Cancer Institute, NIH, 9609 Medical 

Center Drive, Room 7W640, Rockville, 

Maryland 20850, 240–276–7684, 

saejeong.kim@nih.gov. 

Name of Committee: National Cancer 

Institute Initial Review Group; Institutional 

Training and Education Study Section (F). 

Date: October 18–19, 2021. 

Time: 10:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute at Shady 

Grove, 9609 Medical Center Drive, Room 

7W234, Rockville, Maryland 20850 

(Telephone Conference Call). 

Contact Person: Adriana Stoica, Ph.D., 

Scientific Review Officer, Resources and 

Training Review Branch, Division of 

Extramural Activities, National Cancer 

Institute, NIH, 9609 Medical Center Drive, 

7W234, Rockville, Maryland 20850, 240– 

276–6368, Stoicaa2@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; Centers on 

Telehealth Research for Cancer-Related Care 

(P50 Clinical Trial Required). 

Date: October 20–21, 2021. 

Time: 9:00 a.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute at Shady 

Grove, 9609 Medical Center Drive, Room 

7W108, Rockville, Maryland 20850 

(Telephone Conference Call). 

Contact Person: Clifford W. Schweinfest, 

Ph.D., Scientific Review Officer, Special 


lotter on DSK11XQN23PROD with NOTICES1